The University of Chicago Header Logo

Rita Nanda

Concepts (321)

Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.


Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Triple Negative Breast Neoplasms
28
2025
169
7.680
Why?
Breast Neoplasms
69
2025
3022
5.980
Why?
Neoadjuvant Therapy
34
2025
376
3.640
Why?
Receptor, ErbB-2
31
2025
247
3.010
Why?
Antineoplastic Combined Chemotherapy Protocols
38
2024
2507
2.610
Why?
Antibodies, Monoclonal, Humanized
15
2024
952
2.260
Why?
Biomarkers, Tumor
24
2025
1545
1.800
Why?
Receptors, Estrogen
13
2025
394
1.580
Why?
Immunotherapy
8
2025
699
1.390
Why?
Programmed Cell Death 1 Receptor
4
2024
173
1.350
Why?
Immunoconjugates
4
2024
114
1.340
Why?
Receptors, Progesterone
9
2025
175
1.240
Why?
Neoplasm Staging
21
2024
2000
1.210
Why?
B7-H1 Antigen
7
2024
279
1.210
Why?
Female
94
2025
46617
1.120
Why?
Trastuzumab
17
2024
73
1.080
Why?
Complementary Therapies
2
2024
56
1.080
Why?
Camptothecin
4
2024
195
1.080
Why?
Paclitaxel
13
2024
474
1.070
Why?
Antineoplastic Agents
9
2022
2331
0.990
Why?
Antineoplastic Agents, Immunological
4
2023
204
0.990
Why?
Integrative Medicine
1
2024
10
0.930
Why?
Humans
105
2025
90014
0.860
Why?
Middle Aged
59
2025
26173
0.800
Why?
Tumor Microenvironment
6
2024
476
0.780
Why?
Adult
50
2025
26836
0.690
Why?
Aged
44
2025
19272
0.680
Why?
Neoplasm Metastasis
15
2024
1066
0.670
Why?
Genes, BRCA1
3
2011
192
0.630
Why?
Age Factors
1
2023
1880
0.610
Why?
Pharmacogenetics
5
2019
437
0.570
Why?
Precision Medicine
7
2023
413
0.570
Why?
Circulating Tumor DNA
3
2023
48
0.550
Why?
Neoplasm Recurrence, Local
8
2024
1355
0.550
Why?
Capecitabine
4
2024
93
0.540
Why?
Receptors, Androgen
3
2024
119
0.520
Why?
Poly(ADP-ribose) Polymerase Inhibitors
5
2021
78
0.510
Why?
Antibodies, Monoclonal
5
2024
1396
0.500
Why?
Disease-Free Survival
9
2024
1169
0.470
Why?
Antimetabolites, Antineoplastic
4
2021
233
0.470
Why?
Treatment Outcome
19
2024
8292
0.460
Why?
Clinical Decision-Making
5
2021
281
0.450
Why?
Quinazolines
5
2023
212
0.390
Why?
Prognosis
13
2025
3800
0.380
Why?
Genes, erbB-2
2
2009
25
0.370
Why?
Breast
7
2023
292
0.370
Why?
Class I Phosphatidylinositol 3-Kinases
3
2023
64
0.370
Why?
Piperazines
3
2021
283
0.360
Why?
Aged, 80 and over
14
2024
6787
0.340
Why?
Magnetic Resonance Imaging
6
2024
3481
0.330
Why?
Mastectomy
3
2018
246
0.320
Why?
Receptors, Glucocorticoid
2
2024
135
0.320
Why?
Drug Prescriptions
3
2019
141
0.310
Why?
Gene Expression Profiling
7
2025
1452
0.300
Why?
Neoplasms
5
2021
3067
0.290
Why?
Neoplastic Cells, Circulating
2
2020
70
0.290
Why?
Retrospective Studies
10
2025
9237
0.290
Why?
Antineoplastic Agents, Hormonal
2
2021
145
0.280
Why?
Clinical Trials as Topic
3
2022
1134
0.270
Why?
Healthcare Disparities
4
2025
432
0.270
Why?
Benzimidazoles
2
2017
107
0.260
Why?
Cohort Studies
6
2023
2887
0.260
Why?
Carboplatin
2
2017
312
0.250
Why?
Hormones
2
2023
139
0.250
Why?
DNA Methylation
5
2022
666
0.250
Why?
Maytansine
2
2021
10
0.240
Why?
Molecular Targeted Therapy
4
2021
280
0.240
Why?
Genes, BRCA2
1
2005
161
0.240
Why?
Sirolimus
3
2014
162
0.220
Why?
Phthalazines
2
2021
46
0.220
Why?
Mastectomy, Segmental
1
2024
101
0.220
Why?
Genetic Testing
2
2018
543
0.220
Why?
Lymphocytes, Tumor-Infiltrating
1
2024
135
0.220
Why?
Survival Rate
4
2021
1899
0.220
Why?
Yoga
1
2023
5
0.210
Why?
Meditation
1
2023
5
0.210
Why?
Pharmacogenomic Testing
3
2019
95
0.210
Why?
Proteomics
1
2024
232
0.210
Why?
Single-Cell Analysis
1
2024
156
0.210
Why?
Mammary Neoplasms, Animal
1
2022
57
0.200
Why?
Anthracyclines
1
2022
38
0.200
Why?
Recombinant Fusion Proteins
1
2024
563
0.200
Why?
United States
6
2025
7114
0.190
Why?
T-Lymphocytes, Regulatory
1
2024
312
0.190
Why?
Cell-Free Nucleic Acids
1
2023
83
0.190
Why?
Chemotherapy, Adjuvant
4
2024
476
0.190
Why?
Doxorubicin
4
2024
293
0.190
Why?
Phenylthiohydantoin
2
2019
46
0.190
Why?
Contrast Media
2
2023
1084
0.190
Why?
Electron Transport Complex I
1
2021
31
0.190
Why?
Benzamides
3
2019
234
0.180
Why?
Specimen Handling
1
2021
103
0.180
Why?
Lymph Nodes
1
2024
550
0.180
Why?
Brain Neoplasms
2
2018
784
0.180
Why?
Telemedicine
1
2023
195
0.180
Why?
Homologous Recombination
1
2020
53
0.180
Why?
Neoplasms, Hormone-Dependent
1
2020
36
0.170
Why?
Drug-Related Side Effects and Adverse Reactions
2
2020
201
0.170
Why?
Germ-Line Mutation
4
2020
347
0.170
Why?
Point-of-Care Systems
2
2019
146
0.170
Why?
Decision Support Systems, Clinical
2
2017
102
0.170
Why?
Imidazoles
2
2019
140
0.170
Why?
Health Knowledge, Attitudes, Practice
1
2024
540
0.160
Why?
Pyridines
1
2021
300
0.160
Why?
Ovarian Neoplasms
1
2005
772
0.160
Why?
Prescription Drugs
1
2019
34
0.160
Why?
Chemoradiotherapy, Adjuvant
1
2018
36
0.150
Why?
Cyclophosphamide
3
2024
301
0.150
Why?
Mutation
8
2023
4169
0.150
Why?
CTLA-4 Antigen
1
2018
140
0.150
Why?
Combined Modality Therapy
5
2023
1704
0.150
Why?
Genomics
3
2024
778
0.150
Why?
Radiosurgery
1
2021
287
0.150
Why?
Gene Expression Regulation, Neoplastic
5
2025
1284
0.150
Why?
Carcinoma, Ductal, Breast
3
2014
160
0.140
Why?
Albumins
2
2015
129
0.140
Why?
Medical Order Entry Systems
1
2017
27
0.140
Why?
BRCA1 Protein
2
2017
205
0.140
Why?
Practice Guidelines as Topic
2
2021
1055
0.140
Why?
PTEN Phosphohydrolase
1
2017
137
0.140
Why?
Neoplasm, Residual
3
2023
181
0.140
Why?
Protein Kinase Inhibitors
3
2019
586
0.130
Why?
Dasatinib
1
2016
38
0.130
Why?
L-Lactate Dehydrogenase
1
2016
71
0.130
Why?
Diphosphonates
1
2016
34
0.130
Why?
BRCA2 Protein
1
2017
161
0.130
Why?
Quinolines
1
2016
86
0.130
Why?
DNA, Neoplasm
1
2016
266
0.130
Why?
Bone Density Conservation Agents
1
2016
44
0.130
Why?
Physician's Role
1
2017
176
0.130
Why?
Physician-Patient Relations
2
2019
625
0.120
Why?
Meningeal Carcinomatosis
1
2015
7
0.120
Why?
Image Processing, Computer-Assisted
1
2021
1255
0.120
Why?
Vascular Endothelial Growth Factor A
2
2014
405
0.120
Why?
Mifepristone
1
2014
33
0.120
Why?
Meningeal Neoplasms
1
2015
66
0.120
Why?
Esophagitis
1
2014
43
0.120
Why?
Fluorodeoxyglucose F18
1
2015
142
0.120
Why?
Radiation-Sensitizing Agents
1
2014
97
0.110
Why?
Disease Progression
4
2023
1469
0.110
Why?
Genome, Human
1
2019
791
0.110
Why?
Nanoparticles
1
2015
165
0.110
Why?
Bone Neoplasms
1
2016
321
0.110
Why?
Oligonucleotide Array Sequence Analysis
4
2014
693
0.110
Why?
Follow-Up Studies
4
2024
3684
0.110
Why?
Bayes Theorem
3
2024
382
0.110
Why?
Radiation Injuries
1
2014
161
0.110
Why?
Young Adult
6
2021
6418
0.100
Why?
Proportional Hazards Models
3
2020
848
0.100
Why?
Immunohistochemistry
4
2024
1801
0.100
Why?
Nitriles
3
2019
156
0.100
Why?
Carcinoma in Situ
1
2012
52
0.100
Why?
Practice Patterns, Physicians'
1
2017
608
0.100
Why?
Predictive Value of Tests
4
2021
1732
0.090
Why?
ErbB Receptors
2
2011
499
0.090
Why?
Kinetics
2
2023
1534
0.090
Why?
Macrophages
1
2013
582
0.080
Why?
Prospective Studies
4
2020
4329
0.080
Why?
Promoter Regions, Genetic
3
2007
961
0.080
Why?
Guidelines as Topic
2
2021
158
0.080
Why?
Angiogenesis Inhibitors
1
2011
293
0.080
Why?
Logistic Models
2
2016
1214
0.070
Why?
Lymphatic Metastasis
2
2024
495
0.070
Why?
Fanconi Anemia Complementation Group F Protein
1
2007
6
0.070
Why?
Cell Line, Tumor
3
2024
2588
0.070
Why?
Maximum Tolerated Dose
2
2021
263
0.070
Why?
Transcriptome
2
2023
661
0.070
Why?
Ubiquitin-Protein Ligases
1
2007
173
0.070
Why?
Estrogen Receptor alpha
1
2007
148
0.070
Why?
Animals
3
2022
27536
0.070
Why?
Genes, Neoplasm
1
2006
38
0.070
Why?
Patient Selection
2
2021
682
0.070
Why?
Epigenesis, Genetic
3
2022
521
0.070
Why?
Survival Analysis
3
2018
1497
0.060
Why?
Aneuploidy
1
2005
57
0.060
Why?
Disease Management
2
2019
327
0.060
Why?
Chromosomes, Human, Pair 17
1
2005
108
0.060
Why?
Conserved Sequence
1
2006
211
0.060
Why?
Male
8
2023
42705
0.060
Why?
Probability
1
2005
351
0.060
Why?
Sensitivity and Specificity
2
2023
2018
0.060
Why?
Receptor, TIE-2
1
2024
18
0.060
Why?
Drug Resistance, Neoplasm
1
2007
606
0.050
Why?
Personal Satisfaction
1
2023
64
0.050
Why?
Biology
1
2023
52
0.050
Why?
Liquid Biopsy
1
2023
36
0.050
Why?
Carcinoma, Lobular
2
2014
81
0.050
Why?
Biopsy
2
2017
1184
0.050
Why?
Demography
1
2023
183
0.050
Why?
Methylation
1
2023
269
0.050
Why?
Models, Statistical
1
2005
576
0.050
Why?
Risk Factors
2
2018
5562
0.050
Why?
Amenorrhea
1
2021
28
0.050
Why?
Time Factors
2
2021
5361
0.050
Why?
Data Accuracy
1
2021
32
0.050
Why?
Drug Discovery
2
2015
107
0.050
Why?
United States Food and Drug Administration
1
2021
135
0.050
Why?
Bridged-Ring Compounds
1
2020
13
0.040
Why?
Ferredoxin-NADP Reductase
1
2020
15
0.040
Why?
Methylenetetrahydrofolate Reductase (NADPH2)
1
2020
27
0.040
Why?
Patient Satisfaction
1
2023
462
0.040
Why?
Oxazepines
1
2019
4
0.040
Why?
Taxoids
1
2020
124
0.040
Why?
Androgen Receptor Antagonists
1
2019
20
0.040
Why?
Longitudinal Studies
1
2023
1082
0.040
Why?
DNA Mutational Analysis
1
2021
528
0.040
Why?
Postmenopause
1
2020
102
0.040
Why?
Drug Recalls
1
2019
12
0.040
Why?
Heterocyclic Compounds, 3-Ring
1
2019
31
0.040
Why?
Receptors, Steroid
1
2019
42
0.040
Why?
Neoplasm Invasiveness
2
2014
569
0.040
Why?
Bevacizumab
1
2020
268
0.040
Why?
Everolimus
1
2018
35
0.040
Why?
Europe
1
2019
324
0.040
Why?
High-Throughput Nucleotide Sequencing
1
2021
490
0.040
Why?
Genotyping Techniques
1
2018
69
0.040
Why?
Research
1
2019
251
0.040
Why?
Societies, Medical
1
2021
584
0.040
Why?
Pandemics
1
2023
778
0.040
Why?
Poly (ADP-Ribose) Polymerase-1
1
2017
25
0.040
Why?
Proto-Oncogene Proteins c-akt
1
2019
341
0.040
Why?
Drug Labeling
1
2017
40
0.040
Why?
DNA Copy Number Variations
1
2018
181
0.040
Why?
Dose-Response Relationship, Drug
1
2021
1929
0.030
Why?
California
1
2017
146
0.030
Why?
CpG Islands
2
2007
158
0.030
Why?
Health Personnel
1
2019
214
0.030
Why?
Social Perception
1
2017
94
0.030
Why?
Drug Screening Assays, Antitumor
1
2016
78
0.030
Why?
src-Family Kinases
1
2016
74
0.030
Why?
Attitude to Health
1
2017
222
0.030
Why?
Kaplan-Meier Estimate
1
2018
855
0.030
Why?
Vertical Dimension
1
1995
1
0.030
Why?
Orthodontics, Corrective
1
1995
3
0.030
Why?
Malocclusion
1
1995
7
0.030
Why?
Receptors, TNF-Related Apoptosis-Inducing Ligand
1
2015
3
0.030
Why?
Azacitidine
2
2006
148
0.030
Why?
Gene Frequency
1
2017
687
0.030
Why?
Genotype
1
2020
1852
0.030
Why?
Communication
1
2019
461
0.030
Why?
Retreatment
1
2015
107
0.030
Why?
Cell Count
1
2015
199
0.030
Why?
Academic Medical Centers
1
2017
385
0.030
Why?
Analysis of Variance
2
2013
899
0.030
Why?
Lung Neoplasms
1
2006
2370
0.030
Why?
Alleles
1
2017
1137
0.030
Why?
Fatal Outcome
1
2014
296
0.030
Why?
Risk Assessment
1
2021
2327
0.030
Why?
Insulin-Like Growth Factor Binding Protein 3
1
2013
21
0.030
Why?
Insulin-Like Growth Factor II
1
2013
33
0.030
Why?
Positron-Emission Tomography
1
2015
338
0.030
Why?
Receptor, IGF Type 1
1
2013
44
0.030
Why?
Delivery of Health Care
1
2018
437
0.030
Why?
Dexamethasone
1
2014
343
0.030
Why?
Insulin-Like Growth Factor I
1
2013
114
0.030
Why?
Chemoradiotherapy
1
2015
306
0.030
Why?
Triazoles
1
2013
104
0.030
Why?
Induction Chemotherapy
1
2013
152
0.020
Why?
Polymorphism, Single Nucleotide
1
2020
2415
0.020
Why?
Quality of Life
1
2020
1682
0.020
Why?
Extracellular Matrix
1
2013
245
0.020
Why?
Drug Administration Schedule
1
2013
865
0.020
Why?
Neoplasm Grading
1
2013
376
0.020
Why?
Surveys and Questionnaires
1
2019
2658
0.020
Why?
Up-Regulation
1
2013
726
0.020
Why?
Neuroblastoma
1
2014
400
0.020
Why?
DNA-Binding Proteins
2
2006
1243
0.020
Why?
Carcinoma, Hepatocellular
1
2014
399
0.020
Why?
Adolescent
2
2020
9347
0.020
Why?
Senegal
1
2009
4
0.020
Why?
Nigeria
1
2009
157
0.020
Why?
Health Surveys
1
2009
240
0.020
Why?
Apoptosis
1
2015
1718
0.020
Why?
Transcription Factors
2
2006
1665
0.020
Why?
Liver Neoplasms
1
2014
755
0.020
Why?
Genetic Markers
1
2008
476
0.020
Why?
Cyclin A1
1
2006
2
0.020
Why?
Cathepsin K
1
2006
3
0.020
Why?
MSX1 Transcription Factor
1
2006
3
0.020
Why?
Carcinoma, Adenosquamous
1
2006
12
0.020
Why?
Cyclin A
1
2006
29
0.020
Why?
Cathepsins
1
2006
21
0.020
Why?
DNA Modification Methylases
1
2006
28
0.020
Why?
T-Lymphocytes
1
2013
1221
0.020
Why?
DNA Repair
1
2008
363
0.020
Why?
Keratin-5
1
2006
3
0.020
Why?
Keratin-6
1
2006
3
0.020
Why?
Keratins
1
2006
63
0.020
Why?
Neprilysin
1
2006
41
0.020
Why?
Vimentin
1
2006
46
0.020
Why?
Sample Size
1
2006
125
0.020
Why?
Hydroxamic Acids
1
2005
50
0.020
Why?
Reverse Transcriptase Polymerase Chain Reaction
1
2007
885
0.020
Why?
Genes, Tumor Suppressor
1
2006
154
0.020
Why?
Cluster Analysis
1
2006
371
0.020
Why?
Gene Dosage
1
2005
210
0.020
Why?
Tumor Cells, Cultured
1
2006
1048
0.020
Why?
Phosphoproteins
1
2006
261
0.010
Why?
Muscle, Smooth
1
2006
355
0.010
Why?
Tumor Suppressor Proteins
1
2006
290
0.010
Why?
Lymphocytes
1
2005
468
0.010
Why?
Trans-Activators
1
2006
443
0.010
Why?
Actins
1
2006
462
0.010
Why?
Research Design
1
2006
591
0.010
Why?
Colonic Neoplasms
1
2006
572
0.010
Why?
Gene Expression
1
2005
1309
0.010
Why?
Carcinoma, Squamous Cell
1
2006
1098
0.010
Why?
Reproducibility of Results
1
2006
2770
0.010
Why?
RNA, Messenger
1
2005
2026
0.010
Why?
Adenocarcinoma
1
2006
1185
0.010
Why?
Phenotype
1
2006
2457
0.010
Why?
Genetic Predisposition to Disease
1
2006
2360
0.010
Why?
Malocclusion, Angle Class I
1
1995
1
0.010
Why?
Malocclusion, Angle Class II
1
1995
1
0.010
Why?
Mesial Movement of Teeth
1
1995
1
0.010
Why?
Incisor
1
1995
7
0.010
Why?
Tooth Extraction
1
1995
11
0.010
Why?
Cephalometry
1
1995
50
0.010
Why?
Molar
1
1995
22
0.010
Why?
Prostatic Neoplasms
1
2006
1747
0.010
Why?
Child
1
1995
7242
0.000
Why?
Nanda's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (321)
Explore
_
Co-Authors (73)
Explore
_
Similar People (60)
Explore
_
Same Department Expand Description
Explore
_
Physical Neighbors
_